Stopped: Funding for uninsured subjects could not be realized and staffing after COVID hit was also a problem.
While substance use disorders have been found to have relapse rates on part with other chronic illnesses such as hypertension and asthma long term abstinence remains elusive for many. The FDA has recently approve a long acting subcutaneous injectable formulation of buprenorphine. This study aims to determine the feasibility of enrolling and randomizing patients seeking treatment at an outpatient substance abuse clinic to buprenorphine/naloxone films which dissolve under the tongue vs. long acting buprenorphine injection with all other treatment aspects held constant. The study also aims to determine the effectiveness of monthly injections of Sublocade® compared to daily oral Suboxone® SL therapy in the treatment of moderate to severe opioid use disorder after twenty-four weeks of treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Weeks patients continued in treatment during trial period
Timeframe: 26 weeks
Number of Participants that Dropout during the first 28 days of Treatment
Timeframe: first 28 days
Number of participants that complete of the treatment phase
Timeframe: 26 weeks
Number of participants who did not complete the trial in their assigned group
Timeframe: 26 weeks
Percentage of negative urinary drug screens
Timeframe: 26 weeks
Liver enzyme values - ALP, AST, ALT
Timeframe: 26 weeks
Liver enzyme values- Total Bilirubin
Timeframe: 26 weeks
Clinical Opiate Withdrawal Scale (COWS) scores trends
Timeframe: 26 weeks
Subjective Opiate Withdrawal Scale (SOWS) score trends
Timeframe: 26 weeks
Number or patients still in medication assisted therapy (MAT) clinic 6 months after trial period ends.
Timeframe: 6 months
Number of participants death
Timeframe: 6 months